Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Gilead Sciences, Inc. (GILD) vs Koninklijke Philips NV (PHG) Price & Performance

Gilead Sciences, Inc.Trade
Koninklijke Philips NVTrade

Price performance (Past 24H)

Key statistics

Gilead Sciences, Inc. vs Koninklijke Philips NV — how do they compare? Gilead Sciences, Inc. trades at $135.73 (market cap $168.35B), while Koninklijke Philips NV trades at $26.63 (market cap $26.58B). The key difference: Gilead Sciences, Inc. is far larger — about 6.3× Koninklijke Philips NV's market cap, and Koninklijke Philips NV pays the higher dividend (3.75%). Which is the better fit depends on your goals.

GILDPHG
Market Cap
$168.35B$26.58B
Sector
HealthHealth
52-Week High
$155.80$32.91
52-Week Low
$110.56$25.02
Enterprise Value
$191.42B$33.13B
Dividend Yield
2.42%3.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Gilead Sciences, Inc.

Gilead Sciences (GILD) trades at $133.06, down slightly by 0.11% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 8% year-over-year, beating estimates, though a net loss of $6.75 per share resulted from acquisition-related costs. Analyst consensus is strongly bullish with a $151.22 price target, and recent news highlights robust HIV drug sales and pipeline progress.

The outlook for GILD is positive, driven by raised 2026 guidance and HIV franchise strength, but risks include patent cliffs by the mid-2030s and integration challenges from acquisitions. Investors should weigh the high valuation multiples against growth potential, with the stock offering upside if execution continues to exceed expectations.

Koninklijke Philips NV

PHG trades at $26.94, up 0.79% with bullish technical signals and strong earnings beats in recent quarters. The company shows improving fundamentals with 2025 net income of $895M (5.01% margin) and positive cash flow trends. Recent news highlights Exor's increased stake flexibility and institutional buying interest, supporting positive sentiment despite some order timing challenges.

The outlook remains constructive with analyst consensus leaning positive (40.9% buy ratings) and improving profitability. Key risks include competitive pressures and macroeconomic headwinds, but solid execution and shareholder support provide stability for medium-term growth potential.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Read more on GILD

About Koninklijke Philips NV

Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.

Read more on PHG